Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular morbidity over 10years in the CLARICOR randomised, blinded clinical trial
Per Winkel, Jørgen Hilden, Jørgen Fischer Hansen, Jens Kastrup, Hans Jørn Kolmos, Erik Kjøller, Gorm Boje Jensen, Maria Skoog, Jane Lindschou, Christian Gluud, CLARICOR Trial Group
Dive into the research topics of 'Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular morbidity over 10years in the CLARICOR randomised, blinded clinical trial'. Together they form a unique fingerprint.